BioSpace News Archive

XtalPi Inc. (“XtalPi”), a computation-driven pharmaceutical technology company, announced today a strategic research collaboration with Pfizer Inc. (“Pfizer”) to develop a hybrid physics- and artificial intelligence (AI)-powered software platform for accurate molecular modeling of drug-like small molecules.

Company expands Integrated Patient Experience Solutions to Los Angeles Market; Brant Heise and Mark Neaman join Board of Directors

Click Therapeutics, Inc., has been awarded a National Institutes of Health (NIH) Small Business Innovation and Research (SBIR) grant through the National Institute of Drug Abuse (NIDA)

This patent includes RXI-109 and its use in dermal scarring, for which the safety and efficacy was shown in a recent Phase 2 clinical trial with statistically significant outcomes for improved visual appearance for RXI-109 treated scar over control.

During the first quarter ended March 31, 2018, the Company sold two Senhance Systems.

The acquisition is expected to close at the end of May 2018.

First-quarter 2018 net sales were $551.5 million, an increase of 10.3 percent compared to $500.1 million reported for the first quarter of 2017

Motif Bio plc announced that two iclaprim abstracts have been accepted for presentation at the upcoming American Society For Microbiology (ASM) Microbe 2018 meeting to be held in Atlanta, GA, USA, June 7-11, 2018.

The bill specifically provides that proton therapy treatment must be prescribed by a Board-Certified Radiation Oncologist

Aetion Evidence Platform aims to replicate 30 published randomized clinical trials with real-world data analyses